Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
PARKHILL KAREN L | EVP & Chief Financial Officer | Mar 18 | Sale | 110.00 | 682 | 75,020 | 34,946 | Mar 21 07:34 PM | Surface Carol A | SVP, Chief HR Officer | Mar 11 | Sale | 105.30 | 6,000 | 631,800 | 28,502 | Mar 14 05:46 PM | WHITE ROBERT JOHN | EVP & Pres. Medical Surgical | Dec 23 | Sale | 102.04 | 7,218 | 736,525 | 39,430 | Dec 27 06:31 PM | ANDERSON RICHARD H | Director | Dec 16 | Buy | 103.26 | 5,010 | 517,333 | 108,374 | Dec 17 04:57 PM | PARKHILL KAREN L | EVP & Chief Financial Officer | Dec 06 | Sale | 110.00 | 682 | 75,020 | 35,446 | Dec 07 06:23 PM | Lerman Bradley E | SVP General Counsel & Corp Sec | Sep 30 | Option Exercise | 78.00 | 49,147 | 3,833,466 | 97,910 | Oct 01 06:13 PM | Lerman Bradley E | SVP General Counsel & Corp Sec | Sep 30 | Sale | 126.58 | 49,147 | 6,221,027 | 48,763 | Oct 01 06:13 PM | Lerman Bradley E | SVP General Counsel & Corp Sec | Aug 31 | Option Exercise | 74.84 | 50,775 | 3,800,001 | 99,538 | Sep 01 05:27 PM | Lerman Bradley E | SVP General Counsel & Corp Sec | Aug 31 | Sale | 134.17 | 50,775 | 6,812,482 | 48,763 | Sep 01 05:27 PM | Martha Geoffrey | CEO | Aug 25 | Option Exercise | 61.81 | 11,581 | 715,805 | 105,936 | Aug 26 07:26 PM | Salmon Sean | EVP & Pres Diabetes/Cardiovasc | Aug 25 | Option Exercise | 38.71 | 28,419 | 1,100,066 | 54,458 | Aug 26 07:28 PM | Salmon Sean | EVP & Pres Diabetes/Cardiovasc | Aug 25 | Sale | 134.08 | 28,419 | 3,810,492 | 33,329 | Aug 26 07:28 PM | Martha Geoffrey | CEO | Aug 25 | Sale | 132.67 | 11,581 | 1,536,451 | 95,836 | Aug 26 07:26 PM | Lerman Bradley E | SVP General Counsel & Corp Sec | Aug 02 | Sale | 131.52 | 4,000 | 526,080 | 48,194 | Aug 04 06:18 PM | Martha Geoffrey | CEO | Jun 28 | Option Exercise | 55.32 | 11,500 | 636,180 | 93,448 | Jun 30 06:21 PM | Martha Geoffrey | CEO | Jun 28 | Sale | 125.29 | 11,500 | 1,440,835 | 81,948 | Jun 30 06:21 PM | Wall Brett A. | EVP & Pres Neuroscience | Jun 21 | Sale | 123.50 | 115 | 14,202 | 21,602 | Jun 22 05:58 PM | Wall Brett A. | EVP & Pres Neuroscience | Jun 18 | Option Exercise | 74.84 | 1,168 | 87,413 | 22,655 | Jun 22 05:58 PM | PARKHILL KAREN L | EVP & Chief Financial Officer | Jun 15 | Sale | 124.47 | 605 | 75,304 | 86,223 | Jun 17 06:11 PM | Wall Brett A. | EVP & Pres Neuroscience | Jun 01 | Sale | 128.07 | 2,473 | 316,717 | 21,487 | Jun 02 06:00 PM | Liddicoat John R | EVP & President of Americas | May 28 | Option Exercise | 82.73 | 34,656 | 2,866,925 | 77,207 | Jun 01 05:55 PM | Wall Brett A. | EVP & Pres Neuroscience | May 28 | Option Exercise | 47.00 | 12,300 | 578,100 | 31,315 | Jun 02 06:00 PM | Liddicoat John R | EVP & President of Americas | May 28 | Sale | 126.65 | 34,656 | 4,389,182 | 42,551 | Jun 01 05:55 PM |
|